DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for periosteal chondroma — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePeriosteal chondroma maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for periosteal chondroma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
isocitrate dehydrogenase (NADP(+)) 1 (IDH1) — IDH1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ictdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6BKX · 1.65 Å · ligand ISOCITRIC ACID (ICT). Experimental structure, not a prediction.
What the evidence adds up to
Periosteal chondroma is a rare benign cartilaginous tumour that arises adjacent to the cortex beneath the periosteum, usually slow-growing and rarely exceeding 3 cm in greatest dimension. A 2014 case report describes a 17-year-old boy with a giant periosteal chondroma of the right distal femur treated with intralesional resection and intensive curettage, followed by reconstruction using synthetic bone grafts and a bioresorbable plate. A 2006 case report describes a 16-year-old boy with a subtrochanteric periosteal chondroma; the authors stress that conservative surgery with complete excision leads to permanent cure, and that awareness of the lesion’s features helps prevent overtreatment because differentiation from malignant lesions can be extremely difficult even at histology.
A 2021 review notes that periosteal chondroma is also called juxtacortical chondroma, sub-periosteal chondroma, or soft tissue chondroma, and was first described by Lichtenstein and Hall in 1952. The neoplasm arises from hyaline cartilage and frequently erodes bone cortex. Morphological distinction from low-grade chondrosarcoma may be challenging; the review suggests that cytofluorometric analysis of DNA ploidy may assist in separating periosteal chondroma from chondrosarcoma.
No abstracts report any drug treatment for periosteal chondroma. All management described is surgical excision. No randomised trials, no controlled studies, and no data on recurrence rates beyond the claim of permanent cure after complete excision in one case report are available. What is missing is any prospective trial design, any patient stratification beyond individual case reports, and any funding for systematic investigation of this rare tumour.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
World Journal of Surgical Oncology · 2014 · 11 citations · open access
A giant periosteal chondroma of the distal femur successfully reconstructed with synthetic bone grafts and a bioresorbable plate: a case report
AbstractPeriosteal chondromas are rare benign cartilaginous tumors that arise adjacent to the cortex beneath the periosteum. These lesions are usually slow-growing and rarely exceed 3 cm in the greatest dimension. Here, we describe a 17-year-old boy who had a giant periosteal chondroma of the right distal femur, which was treated with intralesional resection and intensive curettage. In addition, we report a novel application of a bioresorbable plate in the management of the large bone defect after resection of a benign bone tumor.
Indian journal of radiology and imaging - new series/Indian journal of radiology and imaging/Indian Journal of Radiology & Imaging · 2006 · 1 citations · open access
Subtrochanteric periosteal chondroma: A case report and tumor overview
AbstractAbstract We report a rare case of subtrochanteric periosteal chondroma in a 16 years boy. The purpose of this presentation is to stress the importance of a proper clinico-radiological and histopathological diagnosis of this lesion. Awareness of the features of this lesion helps to prevent overtreatment of this benign condition, since its differentiation with malignant lesions may be extremely difficult, even at histology; and since conservative surgery with complete excision of the lesion leads to permanent cure.
Journal of Oncology Research Review & Reports · 2021 · 0 citations · open access
The Perimetric Protuberance-Periosteal Chondroma
AbstractPeriosteal chondroma is an exceptional, benign, gradually progressive cartilaginous neoplasm. Additionally designated as juxtacortical chondroma, sub-periosteal chondroma or soft tissue chondroma, the neoplasm was initially chronicled by Lichtenstein and Hall in 1952 [1]. Characteristically, the lesion arises adjacent to or upon the surface of bone cortex within the sub-periosteal region. The neoplasm arising from hyaline cartilage frequently erodes bone cortex.Periosteal chondroma is appropriately diagnosed with imaging studies and cogent histological features. Morphological distinction of periosteal chondroma from low-grade chondrosarcoma may be challenging. Cytofluorometric analysis of deoxy ribonucleic acid (DNA) ploidy may assist segregation of periosteal chondroma from chondrosarcoma.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
